Although HDAC inhibitors negatively regulate HIF and dampen the HIF hypoxic program thereby destabilizing the tumor hypoxic cells, HDAC inhibitors did not have a strong effect against solid tumors in Phase II trials (Table 1). This evidence concerns the gene HDAC9 and neoplasm.